Lantern Pharma

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantern Pharma reports robust Q4 earnings, unveils strategic drug plans

Lantern Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic drug development plans, and a focus on innovation.
The company faces challenges in a competitive landscape but has opportunities in combination therapies, CNS cancer treatments, and engaging key opinion leaders.
Effective financial management and a clear clinical development roadmap are key strengths for Lantern Pharma.
Balancing financial stability with continued investment in research and development will be crucial for sustained growth.

Lantern Pharma advances AI-driven drug development with strong financial backing

Lantern Pharma's Q1 2023 Earnings Call highlighted significant progress in drug development and financial stability, underpinned by a focus on AI and data analytics.
While facing challenges in managing R&D expenses and industry competition, the company's innovative approach and strong cash position position them well for future growth.
Opportunities abound for Lantern Pharma to further leverage AI, explore partnerships, and advance in critical areas like brain cancer drug discovery.
Overall, Lantern Pharma's strategic focus on technology-driven efficiency and innovation sets a promising trajectory for their future in the pharmaceutical landscape.

Lantern Pharma reports promising Q2 results amidst AI-driven advancements

Lantern Pharma's Q2 2023 performance reflects a mix of financial stability, promising drug candidates, and advancements in AI-driven drug development.
The company's strengths lie in its innovative AI-driven strategy, focus on biology, and cost-effective approach to advancing molecules into trials.
Challenges include optimizing trial enrollment, addressing clinician preferences, and navigating the competitive landscape of AI-driven drug discovery.
Opportunities for Lantern Pharma include presenting new data, exploring combination therapies, and leveraging their fit-for-purpose strategy in oncology for future growth.

Lantern Pharma reports Q3 progress, financial stability, and innovation focus

Lantern Pharma's Q3 2023 earnings call highlighted progress in drug development, financial stability with a cash runway into at least Q3 2025, and a focus on innovation through the RADR platform.
While facing challenges such as a net loss and the need to improve financial performance, the company's strengths in pipeline development and technological innovation position them for future growth.
Opportunities lie in leveraging the RADR platform for accelerated drug development, data accumulation in 2024, and pursuing strategic initiatives supported by a strong cash position.
Overall, Lantern Pharma's earnings call reflects a balance of achievements, challenges, and opportunities that shape their trajectory in the pharmaceutical industry.

Lantern Pharma reports Q4 loss, eyes collaborations for growth

Lantern Pharma's Q4 2023 performance reflects a focus on innovation and strategic financial management.
The company's strengths lie in AI-driven drug discovery, diversification efforts, and platform advancements.
Challenges include managing expenses, navigating risks, and ensuring successful execution of growth plans.
Opportunities in collaborations, licensing, and leveraging their platform as a currency offer avenues for expansion.

Lantern Pharma reports Q1 loss, advances AI drug development

Lantern Pharma's Q1 2024 earnings call highlighted financial results, AI-driven drug development, and collaborations.
The company's focus on accelerating drug development and expanding into new indications shows promise for future growth.
Despite challenges in timelines and trial expansions, Lantern Pharma aims for more efficient drug development processes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for pancreatic cancer.  LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.

Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate

DALLAS, Aug. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer.

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer

Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript

DALLAS, July 29, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern"), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the second quarter ended June 30, 2021.

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights

DALLAS, July 27, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity, formerly known as Oncology Venture.

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

DALLAS, July 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m.

Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET

The stock price of Lantern Pharma Inc. (NASDAQ: LTRN) increased by over 10% pre-market. This is why it happened.

LTRN Stock Increases Over 10% Pre-Market: Why It Happened

Lantern Pharma Inc (NASDAQ: LTRN) has announced new preclinical data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center.  These data demonstrated that the drug candidate, LP-184, exhibited significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks.

Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models

DALLAS, July 20, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today positive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center.

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

C3.ai

Invitae

With the global release of 5G connectivity, machine learning has become more of a secular trend than ever before.

3 Little Known AI Stocks for the Future

Lantern owns an AI drug development platform called RADR that increases in value each day as it analyzes more data points. Using this platform, Lantern has generated an impressive internal pipeline of several different drugs including LP-100, LP-300, LP-184, and LP-284.

Lantern Pharma: Drug Recycling With AI

Artificial intelligence is one of the most fascinating and powerful technological advances to come along over the past decade. The idea that we can use machine learning and data to make a positive impact in all different types of industries is certainly attractive from an investing perspective.

Lantern Pharma - Using AI to Transform The Cost & Risk of Cancer Drug Development

Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2021 Results - Earnings Call Transcript

DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the first quarter ended March 31, 2021.

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it has entered into a research and development collaboration with Actuate Therapeutics.

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

DALLAS, April 29, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that RADR® has exceeded 4.6 billion datapoints.

Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's St

DALLAS, April 26, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Monday, May 3, 2021 at 4:30 p.m.

Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET

DALLAS, April 26, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, announced a manuscript describing the efficacy profile of LP-184 in a variety of non-small cell lung cancer models was published in Oncotarget.

Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

Lantern Pharma Inc. is a clinical-stage oncology biotechnology company utilizing AI, machine learning, and genomic data to develop, streamline, rescue, and revitalize small-molecule drugs (oftentimes abandoned or failed) for targeted oncology patients.

Lantern: Changing The Cost-Curve, Changing The Risk, AI-Biotech Unlocks New Value

DALLAS, April 6, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that Panna Sharma, President and CEO of Lantern Pharma, will participate in the 20th Annual Needham Healthcare Conference, to be held virtually on April 12-15, 2021.

Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference

DALLAS, April 1, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D.

Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins

DALLAS, March 23, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.

Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021

DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties.

Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties

DALLAS, March 12, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, today announced that an interview with CEO Panna Sharma will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, March 13, at 7 p.m.

News for Lantern Pharma Stock (LTRN)